Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5906206 | Gene | 2013 | 14 Pages |
Abstract
Therapeutic angiogenesis with vascular endothelial growth factors (VEGFs) is a promising approach for the treatment of ischemic myocardium and peripheral skeletal muscles. Preclinical studies in large animals have clearly demonstrated safety and efficacy of VEGF gene therapy in clinically relevant disease models. However, first clinical trials with intravascular delivery of VEGF vector constructs have only resulted in limited benefits to the patients. Second generation VEGF-based gene therapy trials are based on direct intramyocardial and intraskeletal muscle injections in order to achieve better transfection efficiency and more targeted effects. Phase I/II studies are currently ongoing to test safety, feasibility and efficacy of these improved approaches in patients with severe cardiovascular diseases.
Keywords
AAVAdVGMP18F-FDGlacZ18F-fluorodeoxyglucoseAdenovirusAngiogenesisMRISPECTCardiovascular diseasesMagnetic resonance imagingGood Manufacturing Practicesingle-photon emission computed tomographyPositron emission tomographyTherapyvascular endothelial growth factorsVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Adeno-associated virusPETC-reactive proteinCRP
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Seppo Ylä-Herttuala,